| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.3 | 0.007 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.007 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.096 | 0.007 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.13 | 0.008 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.008 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.008 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.008 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.12 | 0.009 |